Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an
effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been …

Salivary gland neoplasms are a morphologically heterogenous group of lesions that are
often diagnostically challenging. In recent years, considerable progress in salivary gland …

Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently
approved for breast, gastric, and gastroesophageal cancers overexpressing the HER2 …

Salivary duct carcinoma (SDC) is an aggressive subtype of primary salivary gland
carcinoma, often with an advanced stage at presentation and high rates of metastasis and …

Salivary glands carcinomas are very rare epithelial malignant tumors. In 2013 in Europe,
7800 new diagnoses were estimated, 8.5% of all head and neck cancer. The last WHO …

Salivary gland neoplasms are an uncommon and widely heterogeneous group of tumors. In
recent years, there has been considerable progress in efforts to reveal the molecular …

Background Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is
mostly androgen receptor‐positive. Only limited data are available on androgen deprivation …

Background HER2 aberrations in salivary gland carcinomas (SGC) as well as benefit of
HER2 directed therapy have been reported in small studies. However, reliable estimates of …

Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis
and a need for better prognostication and novel treatments. The aim of this national cohort …

Salivary duct carcinoma (SDC) is a prototypic aggressive salivary gland carcinoma. Our aim
is to determine the prevalence of histologic variants (micropapillary, basal-like) and …